Nanoliposomal Auraptene: A Comprehensive Study on Preparation, Characterization, Cytotoxicity, and Anti-Angiogenic Potential
Student Research in Translational Medicine,
Vol. 6 (2024),
24 January 2024
https://doi.org/10.22037/srtm.v6.44191
Abstract
Background: Nanoliposomes are spherical nano-sized capsules enclosed by lipid membranes, serving as a biocompatible vehicle to enhance the delivery of therapeutic agents. The objective of this research is to prepare and characterize nanoliposome-encapsulated auraptene and compare its cytotoxic and anti-angiogenic effects to non-liposomal auraptene.
Methods: Liposomal auraptene was formulated using DSPC/ DSPG/ Cholesterol (molar ratio of 4:1:2) in combination with two different molar ratios of auraptene (0.1 and 0.05). The entrapment efficiency was evaluated using High- Performance Liquid Chromatography (HPLC). Various parameters, including Dynamic Light Scattering (DLS), zeta potential, stability, and release kinetics, were investigated. Subsequently, both liposomal and non-liposomal auraptene, along with bare liposomes, were applied to the MDA-MB-231 cell line for duration of 72 hours at 37°C at varying concentrations. Cytotoxicity was assessed using the MTT assay. Additionally, the study examined the anti-angiogenic effects on the vessels in the chorioallantoic membrane of chick embryos.
Results: The entrapment efficiency of auraptene was found to be satisfactory at 50%. The liposome size ranged from 85 to 241 nm, with a Z-Average of 190.9 nm. The zeta potentials for all formulations were consistently around -55.7, and the Polydispersity Index (PDI) was less than 0.3 for all formulations. The release profile demonstrated approximately 80% drug release over a period of 130 hours. Notably, liposomal auraptene exhibited a significantly lower IC50 value (38.61 (95% Confidence Interval: 30.56 to 48.78)) compared to non-liposomal auraptene (50.36 (95% Confidence Interval: 43.58 to 58.19)) (p = 0.0240).
Conclusion: Moreover, the administration of 2.5 and 5 µM of liposomal auraptene led to a reduction in the vessels within the chorioallantoic membrane at the injection site when compared to the control group.
In summary, the use of biodegradable nanoliposomal carriers improved the solubility, release profile, and stability of auraptene while demonstrating anticancer and anti-angiogenic properties.
- Cytotoxicity
- Angiogenesis
- MDA-MB-231
- Medicinal Plant
- Nanoparticle Drug Delivery System
- Neoplasms
How to Cite
References
Siegel, R.L., et al., Cancer statistics, 2022. CA Cancer J Clin, 2022. 72(1): p. 7-33.
Pecorino, L., Molecular biology of cancer: mechanisms, targets, and therapeutics. 2021: Oxford university press.
Genovese, S. and F. Epifano, Auraptene: a natural biologically active compound with multiple targets. Curr Drug Targets, 2011. 12(3): p. 381-6.
Tanaka, T., et al., Immunomodulatory action of citrus auraptene on macrophage functions and cytokine production of lymphocytes in female BALB/c mice. Carcinogenesis, 1999. 20(8): p. 1471-6.
Jalali, A., et al., Auraptene Promotes THP-1 Polarization to M1 Macrophages and Improves M1 Function. Res J Pharmacog, 2022. 9(1): p. 63-75.
Sakata, K., et al., Dietary supplementation of the citrus antioxidant auraptene inhibits N,N-diethylnitrosamine-induced rat hepatocarcinogenesis. Oncology, 2004. 66(3): p. 244-52.
Gholami, O. and J. Shamsara, Comparison of the cytotoxic effects of umbelliprenin and auraptene. Int J Pharm Pharm Sci, 2016. 8: p. 1-4.
Krishnan, P. and H. Kleiner-Hancock, Effects of Auraptene on IGF-1 Stimulated Cell Cycle Progression in the Human Breast Cancer Cell Line, MCF-7. Int J Breast Cancer, 2012. 2012: p. 502092.
Shiran, M.R., et al., Effect of Auraptene on angiogenesis in Xenograft model of breast cancer. Horm Mol Biol Clin Investig, 2022. 43(1): p. 7-14.
Daneshmand, S., et al., Preparation, characterization, and optimization of auraptene-loaded solid lipid nanoparticles as a natural anti-inflammatory agent: In vivo and in vitro evaluations. Colloids Surf B Biointerfaces, 2018. 164: p. 332-339.
Rivera Díaz, M. and P.E. Vivas-Mejia, Nanoparticles as drug delivery systems in cancer medicine: emphasis on RNAi-containing nanoliposomes. Pharmaceuticals, 2013. 6(11): p. 1361-1380.
Tereshkina, Y.A., et al., Nanoliposomes as drug delivery systems: safety concerns. J Drug Target, 2022. 30(3): p. 313-325.
Goyal, P., et al., Liposomal drug delivery systems–clinical applications. Acta Pharm, 2005. 55(1): p. 1-25.
Immordino, M.L., F. Dosio, and L. Cattel, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine, 2006. 1(3): p. 297-315.
Zaman, J., Addressing solubility through nano based drug delivery systems. J Nanomed Nanotechnol, 2016. 7(376): p. 2.
Danaei, M., et al., Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics, 2018. 10(2): p. 57.
Bangham, A.D. and R. Horne, Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. Journal of molecular biology, 1964. 8(5): p. 660-IN10.
Kim, J.-S., Liposomal drug delivery system. J Pharm Investig, 2016. 46(4): p. 387-392.
Voinea, M. and M. Simionescu, Designing of 'intelligent' liposomes for efficient delivery of drugs. J Cel Mol Med, 2002. 6(4): p. 465-474.
Di Paolo, D., et al., Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment. Tumori, 2008. 94(2): p. 246-53.
Rashidi, M., et al., Evaluating cytotoxic effect of nanoliposomes encapsulated with umbelliprenin on 4T1 cell line. In Vitro Cell Dev Biol Anim, 2017. 53(1): p. 7-11.
Mozafari, M.R., Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett, 2005. 10(4): p. 711-9.
Salari, H., et al., Coadministration of auraptene and radiotherapy; a novel modality against colon carcinoma cells in vitro and in vivo. Int J Radiat Biol, 2020. 96(8): p. 1051-1059.
Misra, R., S. Acharya, and S.K. Sahoo, Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today, 2010. 15(19-20): p. 842-50.
Bürgi, B.R. and T. Pradeep, Societal implications of nanoscience and nanotechnology in developing countries. Curr Sci, 2006: p. 645-658.
Singh, R. and J.W. Lillard, Jr., Nanoparticle-based targeted drug delivery. Exp Mol Pathol, 2009. 86(3): p. 215-23.
Olusanya, T.O.B., et al., Liposomal Drug Delivery Systems and Anticancer Drugs. Molecules, 2018. 23(4): p. 907.
Hobbs, S.K., et al., Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A, 1998. 95(8): p. 4607-12.
Amoabediny, G., et al., Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: A comprehensive review. Int J Polym Mater Po Biomater, 2017. 67(6): p. 383-400.
- Abstract Viewed: 141 times
- PDF Downloaded: 28 times
- TIF Downloaded: 15 times
